CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.
In 2025, companies operating in Brazil will see the lowest average maximum price adjustments legally permitted since 2018, according to the medicines regulator ANVISA.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.
The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.
Brazil’s drug regulator ANVISA has also published its first post-marketing authorization monitoring reports on advanced therapies Yescarta, Zolgenma, Kymriah, Carvykti and Luxturna.
Health technology assessment bodies in England, the US, Canada, Australia, the Netherlands and Colombia have joined forces to produce guidance for drug developers on using surrogate endpoints for cost-effectiveness analyses.
The preliminary budget document supports legislation clawing back funds appropriated for the program.
Vaccine developers should be aware that the framework underpinning the new EU Health Technology Assessment (HTA) Regulation might not be suitable for immunizations, but actions from policymakers and industry could help mitigate some issues, a senior figure from GSK says.
Europe’s vaccines industry wants to make sure immunizations “are not forgotten” by policymakers who are overseeing the EU Health Technology Assessment Regulation. It has highlighted several nuances of vaccines that should be addressed over the coming years.
